Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
For patients doing well on targeted therapies (alectinib, osimertinib) for metastatic NSCLC, what data / guidelines do you use to decide about holding treatment before/after surgical procedures?
Related Questions
In patients with resected stage II-III NSCLC, who completed adjuvant carboplatin and pemetrexed and are PD-L1 high, which immunotherapy would you offer?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
How do you transition between TKIs for stage IV NSCLC with actionable mutations?
Would you consider the combination of amivantamab and lazertinib in a patient with NSCLC harboring an EGFR exon 19 deletion that transformed to small cell carcinoma on osimertinib, if resistance profiling still detects the EGFR mutation?
Is there any data on the safety or efficacy of combining osimertinib-based therapy with HER2-targeted treatment in patients with EGFR-mutant NSCLC and concurrent HER2-positive breast cancer?
Would you provide vitamin B12 supplementation to a patient on pemetrexed therapy if their B12 levels are normal or high?
For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?
Should a patient with resected stage IIIA lung adenocarcinoma harboring an STK11 mutation receive adjuvant immune checkpoint inhibitor therapy following the completion of adjuvant chemotherapy?
